Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: The Endocanabinnoid System And Diabetes - Critical Analyses Of Studies Conducted With Rimonabant.
Author: Murro, Ada Letícia B
Abstract: Rimonabant is the first CB1 receptor inhibitor available in the Brazilian market. This new drug has been approved for the treatment of obese or overweight patients associated with cardiovascular risk factors. In this article it is compared the effects of rimonabant treatment in obese patients with cardiovascular risk factors to usual obesity pharmacological treatment.
Citation: Diabetology & Metabolic Syndrome. v. 1, n. 1, p. 18, 2009.
Rights: aberto
Identifier DOI: 10.1186/1758-5996-1-18
Date Issue: 2009
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_19835615.pdf298.17 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.